Personalis
Fremont, California, United States · Bioinformatics, Biotechnology, Genetics · 50 employees
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment.
Funding history
- Venture - Series Unknown — $12.2M — Jul 2017
Recent signals
- Mar 17, 2026: Personalis Promotes Dr. Richard Chen to President and CMO
- Nov 07, 2025: SEC 8-K (2.01): On November 7, 2025, Personalis, Inc. announced that its ultrasensitive NeXT Personal® test received Medicare coverage for post-treatment surveillance of cancer recurrence specifically in patients with stage II and III breast cancer. This coverage, determined by the Centers for Medicare & Medicaid Services, is effective retroactively from October 7, 2025, and includes a reimbursement rate of $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test. This strategic move is significant as it provides coverage for the plasma test for up to six years post-treatment and allows for the breast test to be administered once per cancer diagnosis, thereby potentially enhancing market accessibility for these tests.
- Jul 18, 2017: Raised $12.2M in Venture - Series Unknown
See plans & pricing → Track Personalis’s funding, hiring, and signals — with verified contacts — on Fundz.